Customers for Life?

Customers for Life?

Up next

Is the Data Center Investing Trend in Trouble?

Description: Snowflake stock is surging towards all-time highs after reporting its latest quarterly earnings, and on today’s show, Jon, Matt, and Lou break down what’s going right for the company in contrast to past years. They also point out some concerns to monitor for Snowflak ...  Show more

Tesla Robotaxi Day & the Competition’s Response

Tesla is having a Robotaxi day tomorrow and we still don’t know details about the event. But that doesn’t mean investors aren’t expecting a lot nearly two years after the Robotaxi was first announced. We discuss the implications for Tesla and why the competition may not be worrie ...  Show more

Recommended Episodes

The business of not dying
Business Daily

Is longevity the next growth industry? We look at why billionaires are betting on 'rejuvenation' tech and whether any of this could help more of us live beyond 100. We meet the entrepreneurs selling 'superfoods', personalised health plans, and longevity consulting, hoping to cash ...  Show more

The $100 billion opportunity: How anti-obesity drugs are reshaping healthcare and consumer behavior
Exchanges

Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices 

Reach Customers, Spend Less With These Expert Tips
Shopify Masters

The marketing landscape is ever changing. Digital advertising costs are rising and there are more restrictions to access customer data. How can businesses navigate these realities and reach their business goals? 

Eric Seufert, founder and partner at Heracles Capital, and ...

  Show more

Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25
CNBC's "Fast Money"

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. Wh ...

  Show more